Venture-capital (VC) funding in biotechnology companies jumped 46 per cent in the second quarter, as investors looked to replenish their portfolios after an increase in acquisitions and IPOs.
VC investing across all sectors rose 19 per cent to $7.5 billion in 966 deals, compared with $6.3 billion and 814 deals in the first quarter of 2011, the National Venture Capital Association and PricewaterhouseCoopers said. The three months that ended June 30 represented the biggest quarter for venture funding in two years.